Reference : Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/70103
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
English
Cummings, S. R. [> > > >]
McClung, M. [> > > >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
Cox, D. [> > > >]
Mitlak, B. [> > > >]
Stock, J. [> > > >]
Amewou-Atisso, M. [> > > >]
Powles, T. [> > > >]
Miller, P. [> > > >]
Zanchetta, J. [> > > >]
Christiansen, C. [> > > >]
Feb-2011
Journal of Bone and Mineral Research
American Society for Bone and Mineral Research
26
2
397-404
Yes (verified by ORBi)
International
0884-0431
1523-4681
Washington
DC
[en] osteoporosis ; fracture ; vertebral fracture ; breast cancer ; arzoxifene ; serms ; randomized ; controlled trial
[en] BACKGROUND: Arzoxifene is a selective estrogen receptor modulator (SERM) more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. METHODS: In a randomized blinded trial, women age 60 to 85 years with osteoporosis, defined as a femoral neck or lumbar spine bone mineral density T-score less than or equal to -2.5 or a vertebral fracture, and women with low bone mass, defined as a bone density T-score less than or equal to -1.0 and above -2.5, were assigned to arzoxifene 20 mg or placebo daily. The primary endpoints were new vertebral fracture in those with osteoporosis, and invasive breast cancer in the overall population. RESULTS: After 3 years, the cumulative incidence of vertebral fractures in patients with osteoporosis was 2.3% lower in the arzoxifene than in the placebo group, a 41% relative risk reduction (95% CI 0.45 to 0.77; P<0.001). In the overall population, the cumulative incidence of invasive breast cancer over 4 years was reduced by 1.3%, with a 56% relative reduction in risk (HR=0.44; 95% CI 0.26 to 0.76; P<0.001); there was no significant decrease in nonvertebral fracture risk. Arzoxifene increased the cumulative incidence of venous thromboembolic events by 0.7%, with a 2.3-fold relative increase (95% CI 1.5 to 3.7). CONCLUSION: Like other SERMs, arzoxifene decreased vertebral fractures and invasive breast cancer while the risk of venous thromboembolic events increased. (c) 2010 American Society for Bone and Mineral Research.
http://hdl.handle.net/2268/70103
10.1002/jbmr.191

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Arzoxifene for prevention of fractures and invasive breast in postmenopausal women.pdfPublisher postprint96.57 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.